Injection site reactions with the use of biological agents-Reference-Cited by-同舟云学术

Injection site reactions with the use of biological agents

Published:2019-01-29 Issue:2 Volume:32 Page:e12817
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Thomaidou Elena¹^ORCID,Ramot Yuval¹^ORCID

Affiliation:

1. Department of DermatologyHadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine Jerusalem Israel

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.12817

Reference27 articles.

1. Hypersensitivity reactions to biological drugs;Corominas M.;Journal of Investigating Allergology and Clinical Immunology,2014

2. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis

3. Injection site reactions to biologic agents used in psoriasis and psoriatic arthritis;Henderson Berg M. H.;Journal of Drugs in Dermatology,2017

4. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

5. Langley R.andPaul C.(2018). How to manage ISRs that occur with injectable agents in psoriasis.Medscape. Retrieved fromhttps://www.medscape.org/viewarticle/884830?src=mkmcmr_driv_stan_mscpedu&uac=46093BX&impID=1445193

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzymatically cross-linked arabinoxylan hydrogel: Effect of glucose oxidase on the gel characteristics and oral colon-targeted delivery for Naja atra neurotoxin;Journal of Food Engineering;2024-12

2. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+);Neurotherapeutics;2024-09

3. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

4. Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database;Expert Opinion on Drug Safety;2024-08-12

5. Non-invasive strategy: Developing a topical IL-4Rα-specific nanobody for the treatment of allergic airway diseases;Materials Today Bio;2024-08